Retatrutide vs Exenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Also: Byetta, Bydureon
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Key Comparison Insights
- Exenatide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
Detailed Comparison
| Attribute | Retatrutide | Exenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. | Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) |
| Administration | Subcutaneous injection weekly | Subcutaneous injection |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 3 TRIUMPH-4 trial (Dec 2025) showed 28.7% weight loss at 68 weeks, with average loss of 71 lbs. Also showed significant osteoarthritis pain relief, reduced cardiovascular risk markers, and 14 mmHg blood pressure reduction. Seven more Phase 3 readouts expected in 2026. NDA submission expected late 2025/early 2026. | First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels. |
Frequently Asked Questions: Retatrutide vs Exenatide
What is the difference between Retatrutide and Exenatide?
Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. expected fda approval late 2026 to early 2027. Exenatide is a weight loss peptide that the first glp-1 receptor agonist approved for diabetes. derived from gila monster saliva. available in twice-daily and weekly formulations. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or Exenatide?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while Exenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and Exenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and Exenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Retatrutide and Exenatide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.